Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Mayne Pharma LLC currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This portfolio is distributed across 2 distinct examiners and 2 distinct art units, indicating a narrow focus in its current prosecution stage. TCHERKASSKAYA, OLGA V is identified as the busiest examiner for this company, currently handling 1 pending office action.
The 2 pending office actions are assigned to the 2 distinct examiners, which suggests that no examiner or art unit dominates the current workload. The presence of 2 distinct art units within the Biotechnology & Pharmaceuticals field may require different strategic approaches depending on the specific technical nuances of each unit. For the practitioner, the fact that there are 2 distinct examiners for 2 pending office actions means that prosecution strategies must be tailored individually.
The workload for TCHERKASSKAYA, OLGA V accounts for 1 pending office action, making the examiner's specific style a significant factor for the company. Practitioners should prioritize analyzing the historical allowance rates and common rejection types associated with this specific examiner and her assigned art unit. This targeted approach is essential when the active portfolio is small enough that individual office actions significantly impact the overall success rate.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TCHERKASSKAYA, OLGA V | 1 | 55.4% | +46.2% |
| KETCHAM, KAREN A | 1 | 20.0% | +38.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17137883 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACNE | KETCHAM, KAREN A | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18128328 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | TCHERKASSKAYA, OLGA V | — |
| 17137883 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACNE | KETCHAM, KAREN A | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18128328 | STABILIZED MICROCAPSULES, METHOD OF THEIR PREPARATION AND USES THEREOF | TCHERKASSKAYA, OLGA V | 1615 | §103§112DP | Final Rejection | — | Pending | Mar 30, 2023 |
| 17137883 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF ACNE | KETCHAM, KAREN A | 1614 | §103 | Final Rejection | — | Pending | Dec 30, 2020 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial